Table 4.

Tissue and serum level of TLR9 according to G (grading) and TN stage in patients with EBV(+) and EBV(−) oropharyngeal cancer.

Parameter	EBV(+)		EBV(−)
	TLR9 in Tissue $\overline{\mathit{X}}$ ± SD	TLR9 in Serum $\overline{\mathit{X}}$ ± SD	TLR9 in Tissue $\overline{\mathit{X}}$ ± SD	TLR9 in Serum $\overline{\mathit{X}}$ ± SD
G1	365.38 ± 174.48	176.56 ± 93.75	721.54 ± 208.81	349.65 ± 86.11
G2–G3	424.0 ± 101.78	190.54 ± 54.76	787.74 ± 184.17	303.24 ± 104.12
P	0.3585	0.4043	0.7372	0.3983
T1–T2	345.8 9 ± 144.81	155.61 ± 71.96	676.52 ± 257.52	308.18 ± 112.52
T3–T4	390.63 ± 130.04	171.09 ± 70.97	675.55 ± 256.02	324.51 ± 115.82
P	0.8545	0.8692	0.9087	0.5806
N1–N2	342.30 ± 133.02	152.61 ± 73.08	721.01 ± 181.60	343.71 ± 92.88
N3–N4	398.85 ± 165.56	189.97 ± 80.97	557.28 ± 295.10	271.83 ± 136.85
p	0.4750	0.4735	0.2571	0.5413

Mann–Whitney U-Test.